Valuation : Signal Genetics Inc

Market Cap 260.91Cr 225.06Cr 211.71Cr 192.87Cr 362.69Cr 25TCr 364.65Cr 2.5TCr 974.14Cr 13TCr 979.59Cr 958.36Cr 42TCr P/E 2026 *
-5.8x
P/E 2027 * -8.93x
Enterprise Value 182.2Cr 157.17Cr 147.84Cr 134.69Cr 253.27Cr 17TCr 254.65Cr 1.75TCr 680.27Cr 8.8TCr 684.08Cr 669.25Cr 29TCr EV / Sales 2026 *
65.3x
EV / Sales 2027 * 9.1x
Free-Float
99.32%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Signal Genetics Inc

Manager TitleAgeSince
Chief Executive Officer 55 30/10/2023
Director of Finance/CFO 46 12/09/2023
Chief Tech/Sci/R&D Officer - 01/01/2024
Director TitleAgeSince
Director/Board Member 74 03/01/2018
Chairman 39 01/06/2021
Director/Board Member 51 14/07/2021
Change 5-day change 1-year change 3-year change Capi.($)
+0.47%-1.67%+2.56%+16.70% 4.97TCr
+2.09%-0.71%+452.73%+498.77% 4.5TCr
-1.09%-0.41%+35.40%+15.17% 4.25TCr
-0.26%-4.71%+17.19%+71.67% 4.08TCr
-0.48%-0.84%+16.25%+49.80% 3.29TCr
-1.06%+2.87% - - 1.71TCr
-1.81%-5.02%+22.65%+113.24% 1.63TCr
+0.22%-1.48%+16.84%+26.26% 1.44TCr
-2.05%-5.14%+72.89%+34.69% 1.35TCr
Average -0.61%-2.44%+79.56%+103.29% 3.02TCr
Weighted average by Cap. -0.36%-2.27%+97.33%+122.17%

Financials

2026 *2027 *
Net sales 2.79Cr 2.41Cr 2.27Cr 2.06Cr 3.88Cr 265.01Cr 3.9Cr 27Cr 10Cr 134.81Cr 10Cr 10Cr 446.99Cr 23Cr 20Cr 19Cr 17Cr 32Cr 2.2TCr 32Cr 222.12Cr 86Cr 1.12TCr 87Cr 85Cr 3.71TCr
Net income -47Cr -40Cr -38Cr -34Cr -65Cr -4.42TCr -65Cr -447.03Cr -173.99Cr -2.25TCr -174.97Cr -171.17Cr -7.46TCr -32Cr -28Cr -26Cr -24Cr -45Cr -3.06TCr -45Cr -308.82Cr -120.2Cr -1.55TCr -120.87Cr -118.25Cr -5.15TCr
Net Debt -79Cr -68Cr -64Cr -58Cr -109.41Cr -7.47TCr -110Cr -755.02Cr -293.87Cr -3.8TCr -295.52Cr -289.11Cr -13TCr -50Cr -43Cr -41Cr -37Cr -70Cr -4.76TCr -70Cr -480.8Cr -187.14Cr -2.42TCr -188.19Cr -184.11Cr -8.02TCr
Logo Signal Genetics Inc
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-